Development
A pancreatic cancer therapy draws a standing ovation
Claim
Revolution Medicines' Daraxonrasib, a once-daily targeted therapy for advanced pancreatic cancer, drew a standing ovation at ASCO.
Reporting date: (not necessarily the event date)
Sources
Attribution and reporting linked by this record; links do not imply independent verification.
- Welcome to June 1, 2026 (theinnermostloop.substack.com)
Cite or correct this record
Suggest a correction — opens a GitHub draft for you to review and submit.